H M Ruottinen
Overview
Explore the profile of H M Ruottinen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
345
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rinne J, Ruottinen H, Nagren K, Aberg L, Santavuori P
Neuropediatrics
. 2002 Aug;
33(3):138-41.
PMID: 12200743
We studied striatal dopamine D1 and D2 receptors in patients with juvenile neuronal ceroid lipofuscinosis (JNCL) with positron emission tomography (PET) using a dopamine D1 receptor antagonist [11C]NNC 756 and...
2.
Nurmi E, Ruottinen H, Bergman J, Haaparanta M, Solin O, Sonninen P, et al.
Mov Disord
. 2001 Aug;
16(4):608-15.
PMID: 11481683
The aim of this study was to investigate the rate of progression in Parkinson's disease (PD) with 6-[(18)F]fluoro-L-dopa (FDOPA) positron emission tomography (PET). We investigated 21 patients with PD and...
3.
Rinne O, Nurmi E, Ruottinen H, Bergman J, Eskola O, Solin O
Synapse
. 2001 Apr;
40(3):193-200.
PMID: 11304757
The aim of this study was to compare two PET ligands, 6-[(18)F]fluoro-L-dopa ([(18)F]FDOPA) and (18)F-labeled CFT, 2beta-carbomethoxy-3beta-(4-[(18)F]-fluorophenyl)tropane ([(18)F]CFT), in detecting presynaptic dopaminergic hypofunction in early Parkinson's disease (PD). These ligands...
4.
Ruottinen H, Niinivirta M, Bergman J, Oikonen V, Solin O, Eskola O, et al.
Synapse
. 2001 Feb;
40(1):19-26.
PMID: 11170218
The aim was to investigate whether the improved 6-[(18)F]fluoro-L-dopa (FDOPA) availability induced by catechol-O-methyltransferase (COMT) inhibition can be more clearly seen during late than during standard (early) imaging in FDOPA...
5.
Lamusuo S, Pitkanen A, Jutila L, Ylinen A, Partanen K, Kalviainen R, et al.
Neurology
. 2000 Jul;
54(12):2252-60.
PMID: 10881249
Objective: To detect reduced [11C]flumazenil in patients with temporal lobe epilepsy (TLE) and to relate binding to histopathology. Methods: The authors studied 16 patients who underwent epilepsy surgery because of...
6.
Nurmi E, Ruottinen H, Kaasinen V, Bergman J, Haaparanta M, Solin O, et al.
Ann Neurol
. 2000 Jun;
47(6):804-8.
PMID: 10852547
We studied the rate of progression of striatal dopamine transporter function in Parkinson's disease (PD). Eight patients with early PD without antiparkinsonian medication and 7 healthy volunteers were investigated with...
7.
Ruottinen H, Partinen M, Hublin C, Bergman J, Haaparanta M, Solin O, et al.
Neurology
. 2000 Feb;
54(2):502-4.
PMID: 10668725
The authors investigated nine drug-naive patients with periodic limb movement disorder and restless legs syndrome (PLMD-RLS) and 27 healthy controls with PET using 6-[18F]fluoro-L-dopa (FDOPA). In the patients, the FDOPA...
8.
Kaasinen V, Ruottinen H, Nagren K, Lehikoinen P, Oikonen V, Rinne J
J Nucl Med
. 2000 Jan;
41(1):65-70.
PMID: 10647606
Unlabelled: Dopamine D2 receptor function was assessed in a PET study with 2 dopamine D2 receptor PET ligands, [11C]raclopride (RAC) and [11C]N-methylspiperone (NMSP), in early Parkinson's disease. Methods: Seven patients...
9.
Lamusuo S, Forss N, Ruottinen H, Bergman J, Makela J, Mervaala E, et al.
Epilepsia
. 1999 Jul;
40(7):921-30.
PMID: 10403216
Purpose: To evaluate combined [18F]fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) and 122-channel whole-scalp magnetoencephalography (MEG) in lateralizing the epileptogenic cortex in patients whose routine presurgical evaluations gave discordant results about...
10.
Ruottinen H, Rinne U
J Neurol
. 1998 Nov;
245(11 Suppl 3):P25-34.
PMID: 9808337
A new approach in the treatment of Parkinson's disease is the inhibition of catechol-O-methyltransferase (COMT) with new generation COMT inhibitors, entacapone and tolcapone. Entacapone acts mainly peripherally whereas tolcapone acts...